Brief: Actinium Pharmaceuticals Inc Announces Phase 3 Iomab-B Sierra Data Accepted For Late-Breaker Presentation At The Transplantation & Cellular Therapy Tandem Meetings
12/01/2023 13:24
Jan 12 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM ANNOUNCES PHASE 3 IOMAB-B SIERRA DATA ACCEPTED
FOR
LATE-BREAKER PRESENTATION AT THE TRANSPLANTATION & CELLULAR
THERAPY TANDEM MEETINGS
* ACTINIUM PHARMACEUTICALS INC - SIERRA TRIAL MET PRIMARY
ENDPOINT
WITH HIGH STATISTICAL SIGNIFICANCE (P<0.0001)
Source text for Eikon: ID:nPn62gBwHa
Further company coverage: ATNM.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities